Mesoblast (MEOBF) Assets Average (2015 - 2026)
Mesoblast's (MEOBF) quarterly Assets Average came in at $777.7 million in Q2 2026, up 8.16% year-over-year from $719.0 million in Q2 2025, and down 0.74% quarter-over-quarter from $783.5 million in Q4 2025.
Analysis
Mesoblast (MEOBF) Assets Average (2015 - 2026) Analysis & Trends
Mesoblast has disclosed Assets Average across 12 years of filings, most recently posting $777.7 million for Q2 2026.
- In Q2 2026, Assets Average rose 8.16% year-over-year to $777.7 million; the TTM figure through Jun 2026 stood at $777.7 million (up 8.16% YoY), while the FY2026 annual figure was $778.9 million, up 7.15% from the prior year.
- Assets Average came in at $777.7 million for Q2 2026 at Mesoblast, down from $783.5 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $783.5 million in Q4 2025 to a low of $659.3 million in Q1 2023.
- Average Assets Average over 5 years is $692.9 million, with a median of $672.6 million recorded in 2022.
- Year-over-year, Assets Average retreated 11.05% in 2022 and increased 18.49% in 2025.
- Over 5 years, Assets Average stood at $676.3 million in 2022, then dropped by 0.95% to $669.8 million in 2023, then slipped by 1.29% to $661.2 million in 2024, then advanced by 18.49% to $783.5 million in 2025, then retreated by 0.74% to $777.7 million in 2026.
- Per Business Quant data, the three most recent Assets Average figures were $777.7 million in Q2 2026, $783.5 million in Q4 2025, and $719.0 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.42 Bn | 112.79 Mn | 1.45 Bn |
| 2 | CRISPR Therapeutics AG | 5.20 Bn | 5.20 Bn | - | 2.69 Bn |
| 3 | Iovance Biotherapeutics | 3.78 Bn | 3.49 Bn | 55.72 Mn | 920.60 Mn |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn | 1.67 Bn |
| 5 | uniQure | 3.06 Bn | 3.06 Bn | 5.49 Mn | 881.90 Mn |
| 6 | Beam Therapeutics | 2.68 Bn | 2.68 Bn | - | 1.43 Bn |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn | 154.46 Mn |
| 8 | Sarepta Therapeutics | 2.35 Bn | 1.55 Bn | 251.87 Mn | 3.18 Bn |
| 9 | Vericel | 2.00 Bn | 1.83 Bn | 56.40 Mn | 494.25 Mn |
| 10 | Mesoblast | 246.02 Mn | 143.11 Mn | - | 777.69 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 777.69 Mn |
| Dec 31, 2025 | 783.50 Mn |
| Jun 30, 2025 | 719.00 Mn |
| Dec 31, 2024 | 661.24 Mn |
| Jun 30, 2024 | 669.72 Mn |
| Dec 31, 2023 | 669.85 Mn |
| Jun 30, 2023 | 659.93 Mn |
| Mar 31, 2023 | 659.25 Mn |
| Dec 31, 2022 | 676.28 Mn |
| Sep 30, 2022 | 673.32 Mn |
| Jun 30, 2022 | 671.92 Mn |
| Mar 31, 2022 | 693.06 Mn |
| Dec 31, 2021 | 713.13 Mn |
| Sep 30, 2021 | 733.27 Mn |
| Jun 30, 2021 | 755.42 Mn |
| Mar 31, 2021 | 726.72 Mn |
| Dec 31, 2020 | 699.94 Mn |
| Sep 30, 2020 | 723.09 Mn |
| Jun 30, 2020 | 699.70 Mn |
| Mar 31, 2020 | 678.01 Mn |